Business Context and Reporting Period
This Form 8-K was filed by Alnylam Pharmaceuticals, Inc. on May 21, 2019, reporting a material event that occurred on the same date following the expiration of the Hart-Scott-Rodino waiting period.
Key Financial Metrics
The filing details a specific equity transaction rather than periodic financial performance metrics (revenue, profit, cash flow, or margins are not reported in this document).
- Transaction Type: Purchase of newly issued common stock.
- Investor: Regeneron Pharmaceuticals, Inc.
- Shares Purchased: 4,444,445 shares.
- Ownership Stake: Approximately 4%.
- Total Consideration: $400 million in cash.
- Price Per Share: $90.00.
Material Changes
Upon the closing of the Equity Transaction, the following agreements became effective:
- The Master Agreement governing the collaboration between Alnylam and Regeneron.
- The Investor Agreement between the parties.
The filing incorporates by reference the detailed terms previously disclosed in the Form 8-K filed on April 9, 2019.
Guidance, Outlook, and Risks
This filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the execution of the previously announced Stock Purchase Agreement. The primary focus is the consummation of the equity placement.
Investor Verification Checklist
- Verify the terms of the Master Agreement and Investor Agreement referenced in the April 9, 2019 Form 8-K.
- Confirm the dilution impact of the 4,444,445 newly issued shares on existing shareholders.
- Review the strategic implications of Regeneron's 4% ownership stake and the associated collaboration framework.
- Check subsequent filings for any additional milestones or payments related to the collaboration agreement.